Home  /   Products  /   Diabetes  /   Human insulin isophane rDNA origin (Biosulin N) subcutaneous 100 IU/ml 10 ml – [1 vial]

Human insulin isophane rDNA origin (Biosulin N) subcutaneous 100 IU/ml 10 ml – [1 vial]


Intermediate-acting human insulin

SKU: 61114 Category:


Biosulin H Pharmacodynamics
A medium-acting insulin preparation. It is a human insulin obtained using recombinant DNA technology.
It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (including hexokinase, pyruvate kinase, glycogen synthetase). Decrease of glucose content in blood is caused by increase of its intracellular transport, intensification of absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, decrease of glucose production rate by liver.
The duration of action of insulin drugs is mainly due to the rate of absorption, which depends on several factors (e.g., dose, route and place of administration), and therefore the action profile of insulin is subject to considerable variation, both in different and in the same patient.
After p/k administration, onset of action is observed after approximately 1-2 h, maximum effect between 6 and 12 h, duration of action 18-24

– Diabetes mellitus type 1 (insulin dependent);
– Type 2 diabetes mellitus (insulin-independent): stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (during combined therapy), intercurrent diseases

– hypoglycemia;
– Hypersensitivity to insulin or other drug components.

Dosage and administration method

  • The drug dose is determined by the physician individually, in each case on the basis of blood glucose levels.
  • The drug is intended for p / n injection. The average daily dose varies from 0.5 to 1 IU/kg of body weight (depending on individual patient and blood glucose levels).
  • The temperature of the administered insulin must correspond to room temperature.
    Biosulin® H is injected p/k into the thigh, injections can also be given into the anterior abdominal wall, buttock or deltoid region of the shoulder.
  • It is necessary to change the injection sites within the anatomical area to prevent the development of lipodystrophy.
  • Biosulin® H can be injected alone or in combination with short-acting insulin (Biosulin® P).